Prevention of Brain Metastases: A New Frontier

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 19

PMID 38893253

Authors

Alessia Pellerino

Tara Marie Davidson

Shreyas S Bellur

Manmeet S Ahluwalia

Hussein Tawbi

Roberta Ruda

Riccardo Soffietti

Affiliations

Soon will be listed here.

Abstract

This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the risk of brain metastasis is related to disease status and molecular subtype (i.e., EGFR-mutant non-small cell lung cancer, HER2-positive and triple-negative breast cancer, BRAF and NRAF-mutant melanoma). Prophylactic cranial irradiation is the standard of care in patients in small cell lung cancer responsive to chemotherapy but at the price of late neurocognitive decline. More recently, several molecular agents with the capability to target molecular alterations driving tumor growth have proven as effective in the prevention of secondary relapse into the brain in clinical trials. This is the case for EGFR-mutant or ALK-rearranged non-small cell lung cancer inhibitors, tucatinib and trastuzumab-deruxtecan for HER2-positive breast cancer and BRAF inhibitors for melanoma. The need for screening with an MRI in asymptomatic patients at risk of brain metastases is emphasized.

References

Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G . Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007; 12(7):766-73. DOI: 10.1634/theoncologist.12-7-766. View

Bander E, Yuan M, Carnevale J, Reiner A, Panageas K, Postow M . Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer. 2021; 127(12):2062-2073. PMC: 9275782. DOI: 10.1002/cncr.33459. View

van der Kooij M, Speetjens F, van der Burg S, Kapiteijn E . Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers (Basel). 2019; 11(6). PMC: 6627906. DOI: 10.3390/cancers11060845. View

Patel S, Macdonald O, Suntharalingam M . Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer. 2009; 115(4):842-50. DOI: 10.1002/cncr.24105. View

Griesinger F, Roeper J, Pottgen C, Willborn K, Eberhardt W . Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. Oncotarget. 2018; 9(80):35181-35194. PMC: 6205553. DOI: 10.18632/oncotarget.26073. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Liu L, Zhao T, Zhong Q, Cui J, Xiu X, Li G . The Role of Prophylactic Cranial Irradiation in Patients With Non-small Cell Lung Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol. 2020; 10:11. PMC: 6989473. DOI: 10.3389/fonc.2020.00011. View

Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M . Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357(7):664-72. DOI: 10.1056/NEJMoa071780. View

10.

Rubenstein J, Dosoretz D, Katin M, Blitzer P, Salenius S, Floody P . Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1995; 33(2):329-37. DOI: 10.1016/0360-3016(95)00166-V. View

11.

Laakmann E, Witzel I, Neunhoffer T, Weide R, Schmidt M, Park-Simon T . Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. Cancers (Basel). 2020; 12(10). PMC: 7600746. DOI: 10.3390/cancers12102787. View

12.

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

13.

Liengswangwong V, Bonner J, Shaw E, Foote R, Frytak S, Richardson R . Prophylactic cranial irradiation in limited-stage small cell lung cancer. Cancer. 1995; 75(6):1302-9. DOI: 10.1002/1097-0142(19950315)75:6<1302::aid-cncr2820750612>3.0.co;2-e. View

14.

Trudeau M, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S . Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006; 17(6):952-6. DOI: 10.1093/annonc/mdl056. View

15.

Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K . Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014; 147(1):103-12. DOI: 10.1007/s10549-014-3090-8. View

16.

Heon S, Yeap B, Lindeman N, Joshi V, Butaney M, Britt G . The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012; 18(16):4406-14. PMC: 3682221. DOI: 10.1158/1078-0432.CCR-12-0357. View

17.

Puente Vazquez J, Lopez-Tarruella Cobo S, Garcia-Saenz J, Casado Herraez A, Moreno Anton F, Gimeno T . Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transl Oncol. 2006; 8(1):50-3. DOI: 10.1007/s12094-006-0095-8. View

18.

Hernandez J, Padilla L, Dakhel S, Coll T, Hervas R, Adan J . Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PLoS One. 2013; 8(9):e72480. PMC: 3762817. DOI: 10.1371/journal.pone.0072480. View

19.

Raez L, Cardona A, Arrieta O, Lopes G . Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy. JCO Glob Oncol. 2020; 6:784-788. PMC: 7328112. DOI: 10.1200/GO.20.00004. View

20.

Mair M, Bartsch R, Le Rhun E, Berghoff A, Brastianos P, Cortes J . Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol. 2023; 20(6):372-389. DOI: 10.1038/s41571-023-00756-z. View